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The plasma membrane-actin linking protein, ezrin, is a glomer-
ular epithelial cell marker in glomerulogenesis, in the adult
kidney and in glomerular injury.
Background. Ezrin belongs to a family of plasma membrane-
cytoskeleton linking, actin binding proteins (Ezrin-radixin-Moesin
family) involved in signal transduction, growth control, cell-cell
adhesion, and microvilli formation.
Methods. The expression of ezrin was examined in glomerular
cells in culture, during kidney development, in the mature kidney,
and in five different experimental kidney disease models in the rat.
Results. Ezrin was specifically expressed in glomerular epithelial
cells in developing glomeruli in mature glomeruli and in glomer-
ular epithelial cells in culture. Distinct from its other family
members, moesin and radixin, which are predominantly expressed
in glomerular endothelial and mesangial areas, ezrin protein (by
immunohistochemistry) was specifically and exclusively modu-
lated during podocyte injury and regeneration. Ezrin immunohis-
tochemistry was able to visualize cell body attenuation, pseudo-
cysts, and in particular vacuolation of injured podocytes, a feature
that usually has to be identified at the ultrastructural level, and
was strikingly increased in binucleated podocytes or podocytes
that were partially or completely detached from the underlying
GBM (frequently also binucleated). Infiltrating macrophages also
express ezrin, but can easily be differentiated from podocytes by
their round shape and higher level of expression.
Conclusions. Ezrin likely has a role in the cytoskeletal organi-
zation, such as reassembling of actin filaments accompanying
podocyte injury and regeneration. Since suitable light microscopic
markers for the identification of glomerular epithelial cells are
rare, ezrin may also be a useful marker for podocytes in normal
and injured glomeruli.
The podocyte is a highly differentiated and specialized
glomerular cell covering the outer surface of the glomeru-
lar basement membrane (GBM), and forms interdigitating
foot processes with slit diaphragms as the last layer of the
glomerular filtration barrier. Beside its role in forming the
glomerular ultrafiltrate, podocytes are thought to counter-
act the hydrostatic pressure in glomerular capillaries [1]
and contribute to the initiation and propagation of glomer-
ular damage, proteinuria, and sclerosis in disease [2–6].
The specialized features of podocytes require a specific
cytoskeletal organization. Although an extensive network
of microtubules, microfilaments and intermediate filaments
containing several contractile components, such as actin,
myosin, and a-actin, has been found in podocytes [7], little
is known about the cytoskeleton of podocytes in physiologic
and pathologic states.
Recently, we have studied the expression of the plasma
membrane-cytoskeleton linking proteins, moesin and ra-
dixin, in glomerular disease [8]. These actin binding pro-
teins were expressed at elevated levels [in response to
platelet-derived growth factor (PDGF), but not basic fibro-
blast growth factor (bFGF)] in activated/migrating mes-
angial cells (MC) predominantly in their filopodial cell
extensions in experimental mesangial proliferative glomer-
ulonephritis (anti-Thy1 model). Another member of this
family of proteins is ezrin, which displays about 75%
identity with moesin and radixin at the amino acid level [9].
Ezrin, like moesin and radixin, interacts with the actin
cytoskeleton and the plasma membrane at specific cellular
locations [10] and is involved in signal transduction and
growth control [9]. Ezrin is the target of various protein
kinases and phosphorylation of ezrin correlated with mem-
brane ruffling activity in A431 cells after EGF-stimulation
[11] or relocalization of ezrin in the microvilli of gastric
parietal epithelial cells [12]. This family of proteins is
thought to be critical for cell-cell adhesion and microvilli
formation [13] and has been characteristically found in very
dynamic structures that undergo changes in cell shape [9].
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While structural and functional (in vitro) similarities be-
tween the members of this family are striking, the different
tissue distribution of ezrin (primarily epithelial cells) and
moesin (primarily endothelial and a restricted set of epi-
thelial cells [14]) implies that these proteins may have
distinct functions uniquely adapted to the specific cell
types.
In this study we examined the expression of ezrin in
cultured glomerular cells, during kidney development, in
the adult kidney, and in glomerular disease. We report that
ezrin is an excellent and specific marker of undifferentiated
and differentiated glomerular epithelial cells during glo-
merulogenesis, in the adult glomerulus, and in all experi-
mental kidney disease models studied. Ezrin protein (as
assessed by immunohistochemistry) was modulated in
podocytes during injury induced by different disease mech-
anisms, and was most strikingly increased in binucleated
podocytes or podocytes that were partially or completely
detached from the underlying GBM. Ezrin is a useful light
microscopic marker of glomerular epithelial cells and may
be an important actin binding protein involved in the
organization of the complex architecture of the podocyte
cytoskeleton in physiologic and pathophysiologic states.
METHODS
Experimental design
Expression of ezrin was analyzed in cultured rat MC,
glomerular epithelial cells (GEC), during renal develop-
ment, and in various glomerular disease models, including
a mesangial proliferative glomerulonephritis model (anti-
Thy1 disease), experimental membranous nephropathy
(passive Heymann nephritis, PHN), aminonucleoside ne-
phritis (PAN), heterologous anti-GBM disease, and glo-
merulosclerosis induced by 5/6 nephrectomy (remnant kid-
ney model). The expression pattern of ezrin was compared
to moesin and radixin. Ezrin protein expression was studied
by immunostaining in: (a) fetal rats (days 18 and 20 of
gestation, N 5 6 each) and newborn rats, N 5 6; (b) normal
adult rats (N 5 6); and (c) at various time points (N 5 3 to
6) after induction of experimental kidney disease. Glomer-
ular expression of ezrin was graded semiquantitatively in a
blinded fashion using a score from 0 to 3 in the different
disease models. In order to identify the cells expressing
ezrin, tissue was double stained for ezrin [15] and specific
cell-type markers for macrophages (ED-1), glomerular
endothelial cells (GEN; such as RECA-1 [16]), mesangial
cells (MC; such as OX-7) and activated MC (a-sm actin
[17]), and a marker for GEC (Wilm’s tumor antigen, WT-1)
[18]. In addition to immunostaining, the expression of ezrin
mRNA was studied by Northern blot analysis, and by in situ
hybridization using antisense 33P-labeled cRNA probes.
Glomerular cell culture
Rat MC and GEC were prepared from normal glomer-
uli, characterized and maintained as described previously
[19].
Kidney development
Kidneys from 6 to 10 (each) rat embryos day 18 and 20 as
well as newborn rats were used for this study.
In vivo disease models
Experimental mesangial proliferative nephritis (anti-
Thy1 model) was induced in 180 to 220 g male Wistar rats
(Simonsen Laboratories, Gilroy, CA, USA) by intravenous
injection of goat anti-rat thymocyte plasma (0.4 cc/100 g
body wt) [20]. Rats were sacrificed and renal biopsies were
obtained on days 3, 5, 7, 10, and 14 (N 5 6 to 9 per group).
Six normal rats (day 0) served as controls. Passive Hey-
mann nephritis, a model of membranous nephropathy, was
induced in male Sprague-Dawley rats (200 to 230 g body wt,
N 5 6; Simonsen Laboratories) by a single intraperitoneal
injection (0.5 ml/100 g) of sheep anti-Fx1A antibody (pre-
pared as described elsewhere) [20]. Control rats were
injected with normal sheep serum. Twenty-four hour pro-
teinuria was assessed in all rats before sacrifice to assure
significant disease. Rats were sacrificed on days 5, 10, 15,
21, and 30 and renal biopsies were obtained. Aminonucleo-
side nephrosis, a model of minimal change disease, was
induced in male Sprague-Dawley rats (200 to 230 g body wt,
N 5 6; Simonsen Laboratories) by a single intravenous
injection of puromycin (0.1 mg/kg; ICN Pharmaceuticals,
Cleveland, OH, USA) [20]. Rats injected with 0.9% NaCl
served as controls (N 5 6). Twenty-four hour proteinuria
was assessed in all rats before sacrifice to assure significant
disease. Rats were sacrificed on days 5, 11, 14, and 21 and
renal biopsies were obtained. Anti-GBM nephritis was
induced in three rats each by a single intravenous injection
of sheep anti-rat GBM antibody as described previously
[21] and renal biopsies were obtained on days 0, 1, and 5. A
model of chronic renal failure accompanied by high blood
pressure, 5/6 nephrectomy, was induced in male Sprague-
Dawley rats (Simonsen Laboratories, 140 to 160 g body wt
at the start of the experiment, N 5 3 to 6) by a right
subcapsular nephrectomy and an infarction of two thirds of
the left kidney via ligation of the posterior and one or two
anterior extrarenal branches of the main renal artery [22].
Sham operated rats served as controls. Animals were
sacrificed at 1, 2, 3, 4, 7.5, and 10 weeks.
Immunohistochemistry
Renal biopsies were fixed in methyl Carnoy’s solution for
immunohistochemistry or 10% formalin for in situ hybrid-
ization studies and embedded in paraffin [17]. Indirect
immunoperoxidase and immunofluorescent staining of 4
mm sections was performed as described previously [17]
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using a specific polyclonal rabbit anti-ezrin antibody
(pAbE) [15]. In addition, tissue was stained with a poly-
clonal rabbit anti-moesin/radixin antibody (pAbMoR) that
specifically recognizes radixin and moesin or an affinity
purified anti moesin antibody (pAbMo) that is specific for
moesin, but not ezrin or radixin as described previously [8,
15], with a murine IgG1 mAb, ED-1, to a cytoplasmic
antigen present in monocytes, macrophages and dendritic
cells (Bioproducts for Science, Inc., Indianapolis, IN,
USA), a murine IgG1 mAb against the endothelial antigen
RECA-1 [16], an affinity-purified rabbit polyclonal Ab
against Wilm’s tumor (WT-1) antigen (Santa Cruz Biotech,
Heidelberg, Germany [18]), a murine IgG1 mAb against
the Thy1 antigen on MC (OX-7; Accurate Chemical Corp.,
Fig. 1. Expression of ezrin protein and mRNA by visceral GEC. By
immunostaining, ezrin was absent in MC (A), but was localized in GEC
primarily to the plasma membrane and cellular extensions such as
filopodia (B, opposite page, top left panel). The nuclear counterstain (red)
was done using propidium iodide. Ezrin mRNA is also expressed in
cultured GEC but not MC (Northern blot) (C). Ezrin protein is also
identified in normal rat glomerular lysates by Western blot using the
polyclonal rabbit anti-ezrin antibody (D).
Fig. 2. Expression of ezrin in rat kidney development and in the adult kidney. In glomeruli from newborn rats, the double immunofluorescent staining
for ezrin (FITC-green) and collagen IV (TRIC-red, for GBM and MC) on ultrathin sections reveals the specific parietal and visceral epithelial cell
expression of ezrin in the developing glomerulus and in proximal tubular cells (A, opposite page, here a day 20 rat embryo). Abbreviations are: bv, blood
vessel; ms, mesangium; Bc, Bowman’s capsule; pt, proximal tubule. The epithelial specificity for ezrin was confirmed by double staining for ezrin (brown)
and WT-1 (black nuclear staining) (B, above). In the adult rat glomerulus, ezrin protein is expressed by visceral and parietal GEC and by proximal
tubular cells (C, above). Double immunostaining for ezrin (FITC-green) and collagen IV (TRIC-red, stains GBM and mesangium) on ultrathin sections
(D, opposite page) demonstrates the exclusive expression of ezrin by podocytes seen at the outer side of the GBM (marked by collagen IV in red). The
capillary lumen is marked by asterisks.
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Fig. 4. Expression of ezrin (by immunostaining) in mesangial cell injury.
In mesangial proliferative glomerulonephritis (A and B, here on day 5)
ezrin protein is constitutively expressed by GEC and also by infiltrating
mononuclear cells (A, arrows) that were shown to be ED-1 positive
macrophages (not shown here). Double immunofluorescent staining (B)
for ezrin in red (Texas red) and alpha sm-actin (a marker of activated MC)
in green demonstrates the non-overlapping distribution of these proteins
during MC injury. A double-labeled cell expressing both ezrin (red) and
a-sm actin (green) would appear orange on the photograph.
Fig. 1 Continued.
Fig. 2, A and D (left).
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Westbury, NY, USA), a murine IgG2 mAb against
a-smooth muscle actin [23] (Sigma Chemical Co, St. Louis,
MO, USA), and a affinity-purified polyclonal goat anti-
human/bovine type IV collagen antibody (Southern Bio-
technology, Birmingham, AL, USA). Negative controls for
immunostaining included either omitting the primary anti-
body or substitution of the primary antibody with equiva-
lent concentrations of an irrelevant murine monoclonal
antibody or preimmune rabbit IgG. For each biopsy, 20 to
50 glomerular cross sections were evaluated in a blinded
fashion. Glomerular expression of ezrin was graded semi-
quantitatively [8] and reflected changes in the intensity of
staining: 0 5 absent staining; 11 5 weak, but identifiable
staining; 21 5 intermediate, clearly increased staining; 31
5 dramatically increased, strong staining.
Immunohistochemical double staining
To determine the cell types expressing ezrin, double
immunostaining with an ezrin-specific antibody and cell
specific markers was performed using an indirect immuno-
fluorescent and/or immunoperoxidase technique [8, 24].
The specific polyclonal ezrin-antibody was incubated over-
night at 4°C, followed by Texas red-or peroxidase-conju-
gated goat anti-rabbit IgG for one hour at reverse tran-
scription (RT). Color development for the peroxidase
staining was done using diaminobenzidine (DAB) without
nickel chloride (NiCl, brown) followed by incubation in 3%
H2O2 in methanol for 20 minutes to prevent any remaining
peroxidase activity prior to application of the second pri-
mary antibody. Afterwards, cell specific antibodies for
glomerular MC (OX-7), GEN (RECA-1), GBM (collagen
IV) or epithelial cells (WT-1) were applied overnight at
4°C, followed by biotinylated rabbit anti-mouse IgG1
(Zymed, San Francisco, CA, USA), and FITC- or peroxi-
dase-conjugated streptavidin D [24]. Color development
for the second antibody was done using DAB with NiCl
(black) or True blue (blue; Kirgaard & Perry Laboratories,
Gaithersburg, MD, USA). To determine whether activated
MCs or infiltrating macrophages specifically express ezrin,
double staining was performed using ezrin specific antibod-
ies with a-sm actin or ED-1 antibodies, respectively, using
an equivalent protocol. Controls for all double staining
procedures consisted of replacing either one of the primary
antibodies with an irrelevant mouse monoclonal antibody
or preimmune rabbit IgG.
High resolution immunostaining of ezrin using ultrathin
cryosections
To increase resolution of ezrin or moesin immunostain-
ing the following technique was applied to additional
20-day-old rat embryos and adult rats. These rats were
sacrificed and their tissues perfused by cannulating the
aorta with isotonic Ringers solution until all the blood was
removed, followed by perfusion with PLP fixative. The
tissues were cut into , 1 mm [3] cubes and post fixed for
one hour at 4°C in PLP. The fixed tissues were rinsed with
PBS and cryoprotected by infiltration with 2.4 M sucrose.
Tissues were kept indefinitely in 2.4 M sucrose at 4°C. 0.5 to
1 mm frozen sections were taken using a Reichard Ultracut
E microtome equipped for cryoultramicrotomy. The sec-
tions were blocked for 10 minutes with 3%BSA, and
stained with primary antibodies for one hour at RT. After
washing with PBS, the sections were stained with FITC- or
Texas Red-conjugated secondary antibodies, washed and
mounted with glycerol and phenylenediamine. The pictures
were taken with an Olymusepifluorescence microscope.
Immunoblotting of ezrin and specificity of the antibodies
Immunoblotting was performed as described previously
[8] and 5 mg of total glomerular protein was loaded per
lane. Amieva and Furthmayr have extensively characterized
the antibodies used in this study, as shown previously [15].
The ezrin antiserum (pAbE) reacted specifically with the 82
kD band of ezrin without crossreactivity to moesin or
radixin [8, 15]. The immunostaining using pAbE could not
be absorbed by adding recombinant moesin and radixin,
while staining using pAbMoR for radixin/moesin or
pAbMo for moesin only could be specifically abolished
adding the recombinant proteins as reported previously [8].
Preparation of total RNA from cultured cells and
isolated glomeruli followed by Northern analysis
Total RNA was extracted from cultured MC and GEC or
isolated glomeruli (differential sieving method as described
previously) with RNAzol B (Cinna/Biotecx Laboratories,
Friendswood, TX, USA) followed by LiCl precipitation
[17]. Ten micrograms of cultured cell or 15 mg of glomer-
ular RNA per lane were electrophoresed through a 3%
formaldehyde, 1% agarose gel and transferred to a nylon
membrane (Hybond N1, Amersham) as described previ-
ously [4]. A fragment of the pig or human ezrin cDNA
clone [25] was isolated, purified with the SpinBind-system
(FMC, Rockland, ME, USA), and radiolabeled with [32p]
dCTP (10 mCi/ml; New England Nuclear, Boston, MA,
USA) by random primer extension. Membranes were pre-
hybridized for 20 minutes, hybridized with 2 3 106 cpm
probe/ml for one to two hours at 68°C in Quickhyb solution
(Stratagene, La Jolla, CA, USA) and washed with 0.1 3
SSPE, 0.1% SDS twice for 30 minutes at 55°C. All North-
ern blots were repeated at least three times with RNA from
different experiments.
In situ hybridization for ezrin mRNA
Ezrin mRNA was detected by in situ hybridization on
formalin-fixed tissue using 32P-labeled anti-sense and
sense-cRNA probes to human ezrin cDNA [25]. Hybridiza-
tion was performed using a protocol of Wilcox et al [26].
After developing, sections were counterstained with hema-
toxylin/eosin, dehydrated and coverslipped.
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Fig. 3. Quantitation of ezrin immunostaining in different experimental
glomerular disease models in the rat. Ezrin immunostaining was assessed
during the time course of these disease models using a semiquantitative
scoring system from 0 to 3 as described in the Methods section. No
significant changes were seen in mesangial proliferative nephritis (anti-
Thy1 disease, A). In all glomerular disease models with podocyte injury
(PHN, B; PAN, C, anti-GBM disease, D; and 5/6 nephrectomy, E) ezrin
immunostaining was significantly modulated during the process of injury/
regeneration. Data are mean 6 SD. *P , 0.01 versus day 0.
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Statistical analysis
All values are expressed as mean 6 SD. Statistical signif-
icance (defined as P , 0.05) was evaluated using the
Student’s t test or one way analysis of variance with
modified t test was performed using the Bonferroni
method.
RESULTS
Ezrin is a glomerular epithelial cell marker in cultured
glomerular cells
Immunohistochemistry, Western blot, and Northern blot
analysis demonstrated that ezrin protein and mRNA were
endogenously expressed in cultured visceral GEC, and
were absent in cultured MC (Fig. 1). GEC staining of ezrin
was predominant in plasma membrane and filopodia and
there was also faint perinuclear staining (Fig. 1B).
Ezrin is an epithelial cell marker in rat kidney
development and in the adult kidney
Immunostaining for ezrin protein in 18, 20-day-old em-
bryonic, and newborn rat kidneys revealed that ezrin is
consistently and specifically expressed in the epithelial cell
clusters characterizing the early vesicle, comma and S-
stages as well as in parietal and visceral epithelial cells of
more mature forms during all stages of glomerulogenesis,
as demonstrated by double immunostaining for ezrin and
collagen IV (characterizing MC and GBM, Fig. 2A) or by
double staining for ezrin and WT-1 (another GEC marker;
Fig. 2B). In addition to its epithelial expression pattern
during glomerulogenesis, ezrin is also expressed in ureteric
buds, most parts of the tubular system, and the urothelium
(not shown). In situ hybridization with antisense but not
sense cRNA for ezrin confirmed expression of ezrin mRNA
in the developing glomeruli (not shown).
In the normal rat glomerulus, ezrin is expressed by
parietal and visceral GEC (Fig. 2C). Unlike its other family
members, moesin and radixin [8], ezrin could not be
detected in GEN or MC. Double immunostaining for ezrin
and collagen IV (stains GBM and MC) on ultrathin
sections clearly demonstrated the exclusive expression of
ezrin on the outer (podocytic) side of the GBM (marked by
collagen IV; Fig. 2D). Double staining with an antibody
against WT-1, which labels GEC in the rat glomerulus [18],
demonstrated colocalization of both proteins (not shown).
The GEC staining pattern for ezrin was also confirmed by
double labeling with cell specific markers for GEN or MC,
using the antibodies RECA-1 or OX-7, respectively. Ezrin
is also expressed in collecting ducts, the urothelium, in the
brush border microvilli on the apical side of proximal
tubular epithelial cells, and in a subset of distal tubules on
the basolateral side (not shown).
Ezrin is a glomerular epithelial cell marker in
experimental glomerular disease
While ezrin is expressed solely by glomerular epithelial
cells in glomeruli in development and in the adult, it could
still be induced by MC and/or GEN in diseased states.
Therefore, we examined ezrin expression in several glomer-
ular disease models in which different glomerular cell types
are injured.
Ezrin is not expressed by MC during experimental mesangial
proliferative glomerulonephritis (anti-Thy1 model). In anti-
Thy1 disease, a model of mesangial proliferative glomeru-
lonephritis with predominant MC injury, ezrin protein
expression by podocytes did not change at any time point
studied (by immunostaining, Figs. 3A, 4A, Table 1; or by in
situ hybridization, not shown). During the time course of
disease, ezrin protein was always expressed by GEC, but
not by regenerating and proliferating MC, as demonstrated
by double staining for ezrin and a-sm-actin (a marker of
activated MC; Fig. 4B). Infiltrating mononuclear cells also
stained strongly positive for ezrin (Fig. 4A) and were
identified as ED-1 positive macrophages (by double immu-
nostaining, not shown).
Ezrin is modulated during podocyte injury. Ezrin expres-
sion was also studied in glomerular disease models in which
injury to the podocyte occurs. In experimental membranous
glomerulopathy (PHN), where podocyte injury is comple-
ment-mediated, ezrin immunostaining was focally in-
creased in podocytes on day 5, and increased in a homog-
enous pattern up to day 30 (Fig. 3B). Strong ezrin
Table 1. Ezrin protein expression in anti-Thy1 nephritis, aminonucleoside nephrosis (PAN), passive Heymann nephritis (PHN), anti-GBM disease
and 5/6 nephrectomy by immunostaining using a semiquantitative visual scoring system (0 to 3)
Days
Anti-Thy1
model PAN PHN
Anti-GBM
disease 5/6 Nephrectomy
Control 1.35 6 0.30 1.50 6 0.25 1.49 6 0.40 1.45 6 0.30 1.05 6 0.40
Day 1/3 1.55 6 0.25 ND ND 2.20 6 0.3a ND
Day 5 1.46 6 0.40 0.80 6 0.3a 2.30 6 0.4a 0.60 6 0.4a ND
Day 7 1.28 6 0.33 ND ND ND 2.70 6 0.1a
Day 10/11 1.50 6 0.22 1.40 6 0.33 2.20 6 0.3a ND ND
Day 14/15 1.10 6 0.20 1.80 6 0.30 2.55 6 0.3a ND ND
Week 3/4 ND 2.10 6 0.2a 2.76 6 0.2a ND 2.70 6 0.3a
Week 7.5 ND ND ND ND 2.10 6 0.24
Week 10 ND ND ND ND 1.85 6 0.38
Data are mean 6 SD, ND means not done.
a P , 0.01 versus control
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immunostaining was especially apparent in binucleated
podocytes (peak on day 10; Fig. 6).
In the aminonucleoside model, ezrin immunostaining
was focally decreased on day 5 (Figs. 3C and 5A). Later in
the disease (days 11 to 14), focal increases of ezrin immu-
nostaining could be observed in some podocytes, whereas
in other podocytes in the same glomerulus ezrin expression
was still diminished. This characteristic inhomogenous pat-
tern of ezrin was gradually replaced by a generalized
increase in ezrin expression in podocytes by day 21 of the
disease (Fig. 5B). Ezrin immunostaining identified areas of
podocytic injury such as adhesion with parietal GEC (Fig.
Fig. 5. Expression of ezrin in models with podocyte injury. Ezrin expression (black) is focally decreased in podocytes in aminonucleoside nephrosis (A,
PAN day 5). This characteristic inhomogenous pattern of ezrin was gradually replaced by a generalized increase in ezrin expression in podocytes by day
21 of disease (B, PAN day 21). Ezrin immunostaining identified features of podocytic injury such as adhesion with parietal GEC (C, PAN day 14),
pseudocyst formation (D, PAN day 14, arrowhead), and podocyte vacuolation (E, PAN day 5, arrowheads) that was maximal between days 5 and 11 of
disease and quite characteristic for PAN. Ezrin (brown) was also shown to colocalize with another GEC marker, WT-1 (black nuclear stain) in podocytes
in aminonucleoside nephrosis (day 11; F).
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5C), pseudocyst formation (Fig. 5D), and podocyte vacuo-
lation (Fig. 5E), which were maximal between days 5 and 11
of disease. Strong ezrin immunostaining was apparent in
polynucleated podocytes on day 11. Moesin/radixin expres-
sion in both models with podocyte injury (PHN, PAN) was
restricted to endothelial/mesangial areas and did not
change substantially in these disease models (data not
shown).
In anti-GBM disease, ezrin was strongly expressed in
podocytes on day 1, but rarely detectable on day 5 of
disease (Fig. 3D). Despite the decreased expression in most
of the podocytes on day 5, ezrin was highly expressed in
podocytes that were either polynucleic (Fig. 6A) or com-
pletely (or almost completely) detached from the GBM
(Fig. 6B,C).
In the 5/6 nephrectomy model where combined endothe-
lial, mesangial, and glomerular epithelial cell injury is
accompanied by systemic and glomerular hypertension and
leads to a remodeling of the glomerular architecture, ezrin
expression was again specific for GEC and transiently as
well as focally increased early (week 1 and 2) and was
decreased late (weeks 7.5 and 10; Fig. 3E). Despite an
overall decrease late in this model, ezrin immunostaining
was increased in areas of adhesions between parietal GEC
and the glomerular tuft with denuded GBM or injured
podocytes. At sites of synechia formation, a dramatic
invasion and/or proliferation of ezrin-positive parietal GEC
could be shown.
Double immunostaining for ezrin and WT-1 (a GEC
marker) in these disease models also demonstrated the
podocyte-specific expression of ezrin protein (Fig. 5F).
The specific modulation of ezrin protein by podocytes in
different glomerular disease models apparent by immuno-
staining was not seen at the mRNA level. Since ezrin
mRNA could not be detected by Northern blot analysis
using 15 mg total RNA per lane prepared from isolated
glomeruli, radioactive in situ hybridization was done and
revealed a constitutive low level expression of ezrin mRNA
in normal glomeruli that did not show any substantial
change in glomeruli, even in disease models where ezrin
expression was clearly modulated at the protein level by
immunostaining (PAN, PHN, 5/6 nephrectomy; data not
shown). Controls using sense cRNA to ezrin were always
negative.
Fig. 6. Ezrin staining identifies mitotic, polynucleic and detached podocytes. The highest levels of ezrin protein expression were observed in
polynucleated podocytes (A, anti-GBM disease day 5) as well as in injured podocytes that were either partially (B, anti-GBM disease day 5) or
completely detached from the GBM (C, anti-GBM disease day 1). Ezrin was also increased in mitotic podocytes (D, PHN day 10).
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Ezrin is increased in mitotic and polynucleic podocytes
as well as in podocytes that were partially or completely
detached from the underlying GBM
In addition to a specific modulation of podocytes in vivo
during injury, the intensity of ezrin immunostaining was
most obviously increased in polynucleated podocytes (Fig.
6). Polynucleated podocytes could be found in PAN, PHN,
and anti-GBM disease and consistently showed strongest
expression of ezrin (by immunohistochemistry, Fig. 6). The
strong intensity of ezrin immunostaining in polynucleated
podocytes compared to the other glomerular cells allowed
easy identification of these cells in tissue sections. Fre-
quently, polynucleated podocytes were partially or com-
pletely detached from the underlying GBM and changed
into big round ezrin positive cells without the typical
appearance of podocytes. Interestingly, mitotic podocytes
were also strongly positive for ezrin (Fig. 6D).
DISCUSSION
Podocytes are specialized glomerular cells important in
the maintenance of the filtration barrier, as well as in the
support of the capillary tuft, GBM turnover and immuno-
logic functions [6]. One of the unique features of podocytes
are their interdigitating foot processes that are thought to
be critical in providing tensile support to the GBM [1].
They exhibit a prominent actin cytoskeleton, but in spite of
this importance, little is known about how these structures
form, how they are maintained, and how the cytoskeleton
influences this and other functions.
In this article, we report that the cytoskeleton-linking
protein, ezrin, is constitutively expressed in GEC. Unlike
the related proteins moesin and radixin, which are ex-
pressed by mesangial cells and endothelial cells [8], ezrin is
expressed only by visceral and parietal GEC in glomeruli.
Ezrin expression (mRNA and protein) could be demon-
strated in GEC in culture, during glomerulogenesis, and in
the adult kidney.
Although ezrin expression was specific for visceral and
parietal GEC within the glomerulus, the intensity of the
immunostaining varied in different glomerular disease
models. Thus, a relative decrease in ezrin immunostaining
was observed in GEC in the aminonucleoside (day 5), the
anti-GBM (day 5) and in the remnant kidney (weeks 7.5
and 10) models. This phenomenon presumably reflects
cytotoxicity to the GEC. In contrast, an increased staining
intensity for ezrin in GEC was noted in the passive Hey-
mann model (days 5 to 30), during the early phase of the
anti-GBM model (day 1), and in the remnant kidney model
(weeks 2 to 3). In none of these instances, however, did we
detect significant changes in ezrin mRNA levels.
One interesting finding was the strong expression of ezrin
in a subset of podocytes undergoing injury and/or prolifer-
ation. Podocyte injury leads to a stereotypic structural
change that includes foot process effacement, vacuoliza-
tion, hypertrophy, cell body attenuation, pseudocyst forma-
tion, and detachment from the GBM [27]. These charac-
teristic maladaptive changes in podocytes have been
observed ultrastructurally in various animal models [28–30]
and in human disease [31] and have been postulated to play
a major role in the pathogenesis of progressive glomerulo-
sclerosis [2]. Identification of these pathologic findings has
usually required ultrastructural (electron microscopy) stud-
ies. However, by using anti-ezrin antibodies, we were able
to identify changes in the podocyte population at the light
microscopic level, such as vacuolization, the appearance of
polynucleic cells, or of cells involved in synechiae forma-
tion, detached cells, and even mitotic podocytes. This
suggests that immunostaining for ezrin may be a sensitive
way of monitoring for GEC injury.
The functions of ezrin are not fully understood. In vitro
studies have implicated ezrin and related cytoskeleton-
linking proteins in microvilli formations, cell adhesion,
migration and growth [9, 13]. Cosedimentation experi-
ments have demonstrated that ezrin preferentially interacts
with cytoplasmic b-, rather than a-actin [32]. This suggests
ezrin may be involved in the modulation of the GEC shape,
contraction, or attachment to the GBM, all actions that
may be critical for GEC function. In this context, the
observation that ezrin expression was highest in mitotic,
binucleated or polynucleic podocytes and in podocytes
completely or nearly detached to the GBM may reflect the
need to adapt to mechanical, toxic or immunological injury.
If adaptation fails, podocytes may become completely
detached, round up and possibly die (by apoptosis or
necrosis). This pathway may be of relevance to glomerular
disease, since loss of podocytes is believed to predispose to
progressive scarring [2].
In conclusion, the plasma membrane-cytoskeleton link-
ing protein, ezrin, is a GEC marker during glomerulogen-
esis, in the mature kidney and during glomerular injury.
Ezrin protein is modulated during podocyte injury and
regeneration in different experimental models. Immuno-
staining of ezrin is considerably enhanced in polynucleated
podocytes or in podocytes that are detached from the
underlying GBM, and this allows for the identification of
features of injured podocytes such as vacuolization by light
microscopy. Ezrin immunohistochemistry is a useful tool
for studying GEC (patho)physiology, and ezrin may be an
important structural and/or signaling protein in mediating
cytoskeletal arrangements during GEC injury.
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APPENDIX
Abbreviations used in this article are: Ang II, angiotensin II; ATS,
anti-thymocyte serum (plasma); BCIP/NBT, 5-Bromo-4-Chloro-3-Indolyl
Phosphate; bFGF, basic fibroblast growth factor; cpm, counts per minute;
DAB, diaminobenzidine; ECM, extracellular matrix; EGF, epidermal
growth factor; FCS, fetal calf serum; GBM, glomerular basement mem-
brane; GEC, glomerular epithelial cell; GEN, glomerular endothelial cell;
ISH, in situ hybridization; MC, mesangial cell; PAN, puromycin amino-
nucleoside nephrosis; PCNA, proliferating cell nuclear antigen; PDGF,
platelet-derived growth factor; PHN, passive Heyman nephritis; sm,
smooth muscle; SSPE, standard saline phosphate EDTA; SSC, standard
saline citrate.
REFERENCES
1. KRIZ W, HACKENTHAL E, NOBILING R, SAKAI T, ELGER M: A role for
podocytes to counteract capillarywall distension. Kidney Int 45:369–
376, 1994
2. KRIZ W, ELGER M, NAGATA M, KRETZLER M, UIKER S, KOEPPEN-
HAGEMANN I, TENSCHERT S, LEMLEY KV: The role of podocytes in the
development of glomerular sclerosis. Kidney Int 45:64–72, 1994
3. COUSER WG, JOHNSON RJ: Mechanisms of progressive renal disease
in glomerulonephritis. Am J Kidney Dis 23:193–8, 1994
4. RENNKE HG: How does glomerular epithelial cell injury contribute to
progressive glomerular damage? Kidney Int 45:58–63, 1994
5. KERJASCHKI D: Dysfunctions of cell biological mechenisms of visceral
epithelial cell (podocytes) in glomerular diseases. Kidney Int 45:300–
313, 1994
6. ADLER S: Glomerular epithelial cells (chapt 31), in Immunologic Renal
Diseases, edited by NEILSON EG, COUSER WG, Philadelphia, Lippin-
cott-Raven Publishers, 1997, pp 1–13
7. DRENCKHAHN D, FRANKE R-P: Ultrastructural organization of con-
tractile and cytoskeletal proteins in glomerular podocytes of chicken,
rat, and man. Lab Invest 59:673–682, 1988
8. HUGO C, HUGO C, PICHLER R, GORDON K, SCHMIDT R, AMIEVA M,
COUSER W, JOHNSON R: The cytoskeletal linking proteins, moesin and
radixin, are upregulated by platelet-derived growth factor, but not
basic fibroblast growth factor in experimental mesangial proliferative
glomerulonephritis. J Clin Invest 97:2499–2508, 1996
9. ARPIN M, ALGRAIN M, LOUVARD D: Membrane-actin microfilament
connections: An increasing diversity of players related to band 4.1.
Curr Opin Cell Biol 6:136–141, 1994
10. TURUNEN O, WAHLSTROM T, VAHERI A: Ezrin has a COOH-terminal
actin-binding site that is conserved in the ezrin protein family. J Cell
Biol 126:1445–1453, 1994
11. BRETSCHER A: Rapid phosphorylation and reorganization of ezrin and
spectrin accompany morphological changes induced in A-431 cells by
epidermal growth factor. J Cell Biol 108:921–930, 1989
12. HANZEL D, REGGIO H, BRETSCHER A, FORTE JG, MANGEAT P: The
secretion-stimulated 80K phosphoprotein of parietal cells is ezrin, and
has properties of a membrane cytoskeletal linker in the induced apical
microvilli. EMBO J 10:2363–73, 1991 [published erratum appears in
EMBO J 10:3978–3981, 1991]
13. TAKEUCHI K, SATO N, KASAHARA H, FUNAYAMA N, NAGAFUCHI A,
YONEMURA S, TSUKITA S, TSUKITA S: Perturbation of cell adhesion
and microvilli formation by antisense oligonucleotides to ERM family
members. J Cell Biol 125:1371–1384, 1994
14. BERRYMAN M, FRANCK Z, BRETSCHER A: Ezrin is concentrated in the
apical microvilli of a wide variety of epithelial cells whereas moesin is
found primarily in endothelial cells. J Cell Sci 105:1025–1043, 1993
15. AMIEVA MR, FURTHMAYR H: Subcellular localization of moesin in
dynamic filopodia, retraction fibers and other structures involved in
substrate exploration, attachment and cell-cell contacts. Exp Cell Res
219:180–196, 1995
16. DUIJVESTIJN AM, VAN GOOR H, KLATTER F, MAJOOR GD, VAN
BUSSEL E, VAN BREDA VRIESMAN PJ: Antibodies defining rat endo-
thelial cells: Reca-1, a pan-endothelial cell-specific monoclonal anti-
body. Lab Invest 66:459–466, 1992
17. JOHNSON RJ, IIDA H, ALPERS CE, MAJESKY MW, SCHWARTZ SM,
PRITZL P, GORDON K, GOWN AM: Expression of smooth muscle cell
phenotype by rat mesangial cells in immune complex nephritis.
Alpha-smooth muscle actin is a marker of mesangial cell proliferation.
J Clin Invest 87:847–858, 1991
18. MUNDLOS S, PELLETIER J, DARVEAU A, BACHMANN M, WINTER-
PRACHT A, ZABEL R: Nuclear localization of the protein encoded by
the Wilm’s tumor gene WT1 in embryonic and adult tissues. Develop-
ment 119:1329–1341, 1993
19. ADLER S, BAKER PJ, JOHNSON RJ, OCHI RF, PRITZL P, COUSER WG:
Complement membrane attack complex stimulates production of
reactive oxygen metabolites by cultured rat mesangial cells. J Clin
Invest 77:762–767, 1986
20. PICHLER R, GIACHELLI CM, LOMBARDI D, PIPPIN J, GORDON K,
ALPERS CE, SCHWARTZ SM, JOHNSON RJ: Tubulointerstitial disease in
glomerulonephritis. Potential role of osteopontin (uropontin). Am J
Pathol 144:915–926, 1994
21. COUSER WG, DARBY C, SALANT DJ, ADLER S, STILMANT MM,
LOWENSTEIN LM: Anti-GBM antibody-induced proteinuria in isolated
perfused rat kidney. Am J Physiol 249:F241–F250, 1985
22. FLOEGE J, BURNS MW, ALPERS CE, YOSHIMURA A, PRITZL P,
GORDON K, SEIFERT RA, BOWEN PDF, COUSER WG, JOHNSON RJ:
Glomerular cell proliferation and PDGF expression precede glomer-
ulosclerosis in the remnant kidney model. Kidney Int 41:297–309, 1992
23. SKALLI O, ROPRAZ P, TRZECIAK A, BENZONANA G, GILLESSEN D,
GABBIANI G: A monoclonal antibody against alpha-smooth muscle
actin: A new probe for smooth muscle cell differentiation. J Cell Biol
103:2787–2796, 1986
24. HUGO C, PICHLER R, MEEK R, GORDON K, KYRIAKIDES T, FLOEGE J,
BORNSTEIN P, COUSER W, JOHNSON RJ: Thrombospondin 1 is ex-
pressed by proliferating mesangial cells in vivo and is upregulated by
PDGF and bFGF. Kidney Int 48:1846–1856, 1995
25. GOULD KL, BRETSCHER A, ESCH FS, HUNTER T: cDNA cloning and
sequencing of the protein-tyrosine kinase substrate, ezrin, reveals
homology to band 4.1. EMBO J 8:4133–4142, 1991
26. WILCOX JN, SMITH KM, SCHWARTZ SM, GORDON D: Localization of
tissue factor in the normal vessel wall and in the atherosclerotic
plaque. Proc Natl Acad Sci USA 86:2839–2843, 1989
27. MUNDEL P, KRIZ W: Structure and function of podocytes: An update.
Anat Embryol 192:385–397, 1995
28. WHITESIDE CI, CAMERON R, MUNK S, LEVY J: Podocytic cytoskeletal
disaggregation and basement-membraner detachment in puromycin
aminonucleoside nephrosis. Am J Pathol 142:1641–1653, 1993
29. SCHWARTZ MW, BIDANI AK, LEWIS EJ: Glomerular epithelial cell
function and pathology following extreme ablation of renal mass. Am J
Pathol 126:315–324, 1986
30. SHIRATO I, SAKAI T, KIMURA K, TOMINO Y, KRIZ W: Cytoskeletal
changes in podocytes associated with foot process effacement in
Masugi nephritis. Am J Pathol 148:1283–1296, 1996
31. COHEN AH, MAMPASO F, ZAMBONI L: Glomerular podocyte degen-
eration in human renal disease. An ultrastructural study. Lab Invest
37:30–42, 1977
32. YAO X, CHENG L, FORTE JG: Biochemical characterization of ezrin-
actin interaction. J Biol Chem 271:7224–7229, 1996
Hugo et al: Ezrin, GEC, cytoskeleton and glomerular disease1944
